Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1467-1470 |
| Number of pages | 4 |
| Journal | Neurological Sciences |
| Volume | 39 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2018 |
Fingerprint
Cite this
Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod. / Ferrè, L; Clarelli, F; Sferruzza, G; Rocca, MA; Mascia, E; Radaelli, M; Sangalli, Francesca; Dalla Costa, G; Moiola, L; Aboulwafa, M; Martinelli Boneschi, F; Comi, G; Filippi, M; Martinelli, V; Esposito, F.
In: Neurological Sciences, Vol. 39, No. 8, 2018, p. 1467-1470.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod
AU - Ferrè, L
AU - Clarelli, F
AU - Sferruzza, G
AU - Rocca, MA
AU - Mascia, E
AU - Radaelli, M
AU - Sangalli, Francesca
AU - Dalla Costa, G
AU - Moiola, L
AU - Aboulwafa, M
AU - Martinelli Boneschi, F
AU - Comi, G
AU - Filippi, M
AU - Martinelli, V
AU - Esposito, F
PY - 2018
Y1 - 2018
N2 - Background: Several studies have shown an association between 25-hydroxyvitamin D (25[OH]D) levels and multiple sclerosis (MS) susceptibility and/or level of disease activity in patients treated with first line drugs. Aims: To investigate whether baseline 25[OH] D values could influence disease activity also during treatment with the second-line drug fingolimod (FTY). Patients and methods: We enrolled 176 MS patients who started FTY at the San Raffaele Hospital (OSR) MS center with available 25[OH]D measurement at the time of treatment start. We then prospectively followed them for 2 years with periodic clinical examinations and MRI scans. Results: We found no linear correlation between baseline 25[OH] D levels and annualized relapse rate (ARR) or time to first relapse. However, we observed that patients with serum 25[OH]D ≥ 100 nmol/l showed a lower number of Gd+ and combined unique activity (CUA) lesions at baseline compared to patients with the lowest 25[OH] D levels (less than 50 nmol/l, p value < 0.05). Moreover, they showed fewer CUA lesions at 2-year follow-up also when accounting for baseline level of disease activity (p value < 0.05). Conclusions: In patients treated with FTY, those with the highest baseline 25(OH)D levels had a significantly lower number of active lesions at baseline; the same effect, even if weaker, was observed also at 2-year follow-up when adjusting for baseline disease activity. Given Vitamin D supplementation safety profile, also if a causal effect has not yet been shown, most of MS patients could probably benefit from 25[OH]D levels above those currently considered to be sufficient. © 2018 Springer-Verlag Italia S.r.l., part of Springer Nature
AB - Background: Several studies have shown an association between 25-hydroxyvitamin D (25[OH]D) levels and multiple sclerosis (MS) susceptibility and/or level of disease activity in patients treated with first line drugs. Aims: To investigate whether baseline 25[OH] D values could influence disease activity also during treatment with the second-line drug fingolimod (FTY). Patients and methods: We enrolled 176 MS patients who started FTY at the San Raffaele Hospital (OSR) MS center with available 25[OH]D measurement at the time of treatment start. We then prospectively followed them for 2 years with periodic clinical examinations and MRI scans. Results: We found no linear correlation between baseline 25[OH] D levels and annualized relapse rate (ARR) or time to first relapse. However, we observed that patients with serum 25[OH]D ≥ 100 nmol/l showed a lower number of Gd+ and combined unique activity (CUA) lesions at baseline compared to patients with the lowest 25[OH] D levels (less than 50 nmol/l, p value < 0.05). Moreover, they showed fewer CUA lesions at 2-year follow-up also when accounting for baseline level of disease activity (p value < 0.05). Conclusions: In patients treated with FTY, those with the highest baseline 25(OH)D levels had a significantly lower number of active lesions at baseline; the same effect, even if weaker, was observed also at 2-year follow-up when adjusting for baseline disease activity. Given Vitamin D supplementation safety profile, also if a causal effect has not yet been shown, most of MS patients could probably benefit from 25[OH]D levels above those currently considered to be sufficient. © 2018 Springer-Verlag Italia S.r.l., part of Springer Nature
U2 - 10.1007/s10072-018-3440-0
DO - 10.1007/s10072-018-3440-0
M3 - Article
VL - 39
SP - 1467
EP - 1470
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - 8
ER -